Method for expansion of stem cells and the use of such cells

Patent metadata

Field	Value
Publication number	US-9309496-B2
Application number	US-201113817726-A
Country	US
Kind code	B2
Filing date	Aug 23, 2011
Priority date	Aug 23, 2010
Publication date	Apr 12, 2016
Grant date	Apr 12, 2016

Abstract

The present invention demonstrates that SALL4A and SALL4B are strong positive regulators of hematopoetic stem cell expansion. HSCs receiving expression of SALL4A or SALL4B are able to achieve a high-level of expansion. Cultures of SALL4-transduced cells results in extensive HSC expansion with over 1000-fold higher levels than controls within 2 to 3 weeks and expanded HSCs show no or very little maturation. Moreover, the expansion occurs quite rapidly with significant HSC growth in just a few days. In addition, SALL4-induced HSC expansion exhibits no impairment of hematopoietic cell differentiation. SALL4 appears to function in the maintenance of an undifferentiated proliferation state and block cell differentiation for HSCs.

First claim

What is claimed is:

1. A method for expanding a hematopoietic stem cell population, the method comprising providing to the stem cell population a Sal-like 4 (SALL4) polypeptide attached to a transport moiety capable of crossing a cell membrane, in an amount effective to expand the stem cell population.

2. The method of claim 1 , wherein the hematopoietic stem cell is an adult hematopoietic stem cell.

3. The method of claim 1 , wherein the hematopoietic stem cell is in or derived from umbilical cord blood, peripheral blood, bone marrow, or spleen.

4. The method of claim 1 , wherein the hematopoietic stem cell is a human stem cell.

5. The method of claim 1 , wherein the transport moiety is a HIV-1transactivator of transcription (TAT) peptide, a Chariot protein, an arginine-rich peptide, an Antennapedia-derived penetratin peptide, a herpes simplex virus type 1 VP22 protein, or a +36 GFP.

6. The method of claim 1 , wherein the SALL4 polypeptide comprises amino acids in the sequence set forth as SEQ ID No: 11 or 12.

7. The method of claim 1 , wherein the stem cell population is expanded 10-fold, 20-fold, 50-fold, 100-fold, or 1000-fold.

8. A method for expanding a hematopoietic stem cell population ex vivo, the method comprising providing to the ex vivo stem cell population Sal-like 4 (SALL4) polypeptide in an amount effective to expand the stem cell population.

9. The method of claim 8 , wherein the cell population is cultured in media comprising 50 ng/ml FMS-like tyrosine kinase-3 (FLT-3), 50 ng/ml Thrombopoietin (TPO), and/or 50 ng/ml Stem cell factor (SCF) or in media comprising 25 ng/ml FMS-like tyrosine kinase-3 (FLT-3), 25 ng/ml Thrombopoietin (TPO), and/or 25 ng/ml Stem cell factor (SCF).

10. The method of claim 8 , wherein the SALL4 polypeptide is encoded by a nucleotide sequence comprising the sequence set forth as SEQ ID No: 5 or 6.

11. The method of claim 8 , wherein a stem cell in the population is transduced with a viral vector comprising nucleotides encoding the SALL4 polypeptide, thereby providing the SALL4 polypeptide to the stem cell population.

12. The method of claim 11 , wherein expression of said SALL4 polypeptide is under the control of an inducible promoter.

13. The method of claim 8 , wherein the hematopoietic stem cell population is an adult hematopoietic stem cell population.

14. The method of claim 8 , wherein the hematopoietic stem cell population is in or derived from umbilical cord blood, peripheral blood, bone marrow, or spleen.

15. A method for treatment of a disorder in a subject requiring a hematopoietic stem cell or an expanded hematopoietic stem cell, the method comprising:
a) obtaining a hematopoietic stem cell population,
b) providing to the stem cell population a composition comprising a Sal-like 4 (SALL4) polypeptide in an effective amount for the expansion of the stem cell population, and
c) transplanting the expanded stem cell population to the subject in an amount effective for the treatment of said disorder.

Assignees

• Ma Yupo
• Univ New York State Res Found

Inventors

• Ma Yupo

Classifications

• C07K14/47 Primary

  from mammals · CPC title

• C12N5/0647

  Haematopoietic stem cells; Uncommitted or multipotent progenitors · CPC title

• A61K35/28

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title

• C12N5/0663 Primary

  Bone marrow mesenchymal stem cells (BM-MSC) · CPC title

• C12N2501/40

  Regulators of development · CPC title